Titanovo Logo
Back to Cell Types

LOX-IMVIHomo sapiens (Human)Cancer cell line

Also known as: LOX, LOXIMVI, LOXIM-VI, LOX IMVI, LOX/IMVI, LOXMVII, LOXIN-VI

🤖 AI SummaryBased on 13 publications

Quick Overview

Human melanoma cell line used in cancer research.

Detailed Summary

LOX-IMVI is a human melanoma cell line derived from a metastatic lesion. It is part of the NCI-60 panel of cancer cell lines, which are widely used for drug screening and cancer research. The cell line is known for its high proliferation rate and is utilized in studies related to drug resistance, metabolic profiling, and gene expression analysis. Research on LOX-IMVI has contributed to understanding the mechanisms of cancer cell survival and therapeutic resistance. It is also used in studies involving the role of glycine in cancer cell proliferation and metabolic reprogramming.

Research Applications

Drug screeningCancer metabolismGene expression analysisDrug resistance mechanismsMetabolic profiling

Key Characteristics

High proliferation ratePart of NCI-60 panelUsed in studies of drug resistanceInvolved in metabolic reprogramming research
Generated on 6/16/2025

Basic Information

Database IDCVCL_1381
SpeciesHomo sapiens (Human)
Tissue SourceAxillary lymph node[UBERON:UBERON_0001097]

Donor Information

Age58
Age CategoryAdult
SexMale

Disease Information

DiseaseAmelanotic melanoma
LineageSkin
SubtypeMelanoma
OncoTree CodeMEL

DepMap Information

Source TypeAcademic lab
Source IDACH-000750_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationNone reportedTP53---PubMed=19787792
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
MutationSimpleBRAFp.Val600Glu (c.1799T>A)Unspecified-PubMed=26214590

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,12
D13S317
11
D16S539
10,12
D18S51
15,18
D19S433
14.2
D21S11
28,31
D2S1338
18,24
D3S1358
14,15
D5S818
11,13
D7S820
9,11
D8S1179
11,13
FGA
21,22
Penta D
9,11
Penta E
5,7
TH01
7,9.3
TPOX
9,11
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

Mob. DNA 7:20.1-20.11(2016).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Vandesompele J.

Sci. Data 3:160052-160052(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

PLoS ONE 9:E92047-E92047(2014).

DOIPubMedPMC

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Hirshfield K.M., Oltvai Z.N., Vazquez A.

Cancer Metab. 1:20.1-20.13(2013).

DOIPubMedPMC

Global proteome analysis of the NCI-60 cell line panel.";

Wilhelm M., Kuster B.

Cell Rep. 4:609-620(2013).

DOIPubMed

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

Cancer Res. 73:4372-4382(2013).

DOIPubMedPMC

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Science 336:1040-1044(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

Yoon C.N., Chang Y.-T.

PLoS ONE 7:E32096-E32096(2012).

DOIPubMedPMC

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

PLoS ONE 7:E31628-E31628(2012).

DOIPubMedPMC

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Kong D.-X., Yamori T.

Bioorg. Med. Chem. 20:1947-1951(2012).

DOIPubMed

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Ambudkar S.V., Gottesman M.M.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Systems-level modeling of cancer-fibroblast interaction.";

Finn S.P., Loda M., Mahmood U., Ramaswamy S.

PLoS ONE 4:E6888-E6888(2009).

DOIPubMedPMC

DNA fingerprinting of the NCI-60 cell line panel.";

Chanock S.J., Weinstein J.N.

Mol. Cancer Ther. 8:713-724(2009).

DOIPubMedPMC

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mol. Cancer Ther. 5:2606-2612(2006).

DOIPubMedPMC

HLA class I and II genotype of the NCI-60 cell lines.";

Morse H.C. 3rd, Stroncek D., Marincola F.M.

J. Transl. Med. 3:11.1-11.8(2005).

DOIPubMedPMC

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

DOIPubMed

Systematic variation in gene expression patterns in human cancer cell lines.

Botstein D., Brown P.O.

Nat. Genet. 24:227-235(2000).

DOIPubMed

Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.

Finlay G.J., Holdaway K.M., Baguley B.C.

Eur. J. Cancer 30A:1370-1376(1994).

DOIPubMed

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

van Zijl P.L.

Eur. J. Cancer 31A:230-237(1995).

DOIPubMed

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX.

Fodstad O., Aamdal S., McMenamin M.G., Nesland J.M., Pihl A.

Int. J. Cancer 41:442-449(1988).

DOIPubMed

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

J. Natl. Cancer Inst. 83:757-766(1991).

DOIPubMed

Web Resources

dtp.cancer.govstrap.nci.nih.gov